HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Related articles in The JI Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baelder, R. Articles by Braun, A. Search for Related Content PubMed PubMed Citation Articles by Baelder, R. Articles by Braun, A. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Asthma

Pharmacological Targeting of Anaphylatoxin Receptors during the Effector Phase of Allergic Asthma Suppresses Airway Hyperresponsiveness and Airway Inflammation¹

Ralf Baelder^2,*, Barbara Fuchs^*, Wilfried Bautsch, Joerg Zwirner, Jörg Köhl, Heinz G Hoymann^*, Thomas Glaab^¶, Veit Erpenbeck^*, Norbert Krug^* and Armin Braun^*

^* Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany; Institute for Microbiology, Immunology and Hospital Hygiene, City Hospital Braunschweig GmbH, Germany; Department of Immunology, University of Göttingen, Germany; Division of Molecular Immunology, Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio; and ^¶ Pneumology, Medical School, Hannover, Germany

Airway hyperresponsiveness and airway inflammation are hallmarks of allergic asthma, the etiology of which is crucially linked to the presence of Th2 cytokines. A role for the complement anaphylatoxins C3a and C5a in allergic asthma was suggested, as deficiencies of the C3a receptor (C3aR) and of complement factor C5 modulate airway hyperresponsiveness, airway inflammation, and Th2 cytokine levels. However, such models do not allow differentiation of effects on the sensitization phase and the effector phase of the allergic response, respectively. In this study, we determined the role of the anaphylatoxins on the effector phase of asthma by pharmacological targeting of the anaphylatoxin receptors. C3aR and C5a receptor (C5aR) signaling was blocked using the nonpeptidic C3aR antagonist SB290157 and the neutralizing C5aR mAb 20/70 in a murine model of Aspergillus fumigatus extract induced pulmonary allergy. Airway hyperresponsiveness was substantially improved after C5aR blockade but not after C3aR blockade. Airway inflammation was significantly reduced in mice treated with the C3aR antagonist or the anti-C5aR mAb, as demonstrated by reduced numbers of neutrophils and eosinophils in bronchoalveolar lavage fluid. Of note, C5aR but not C3aR inhibition reduced lymphocyte numbers in bronchoalveolar lavage fluid. Cytokine levels of IL-5 and IL-13 in bronchoalveolar lavage fluid were not altered by C3aR or C5aR blockade. However, blockade of both anaphylatoxin receptors markedly reduced IL-4 levels. These data suggest an important and exclusive role for C5aR signaling on the development of airway hyperresponsiveness during pulmonary allergen challenge, whereas both anaphylatoxins contribute to airway inflammation and IL-4 production.

Related articles in The JI:

IN THIS ISSUE

The JI 2005 174: 587-588. [Full Text]  

This article has been cited by other articles:

				M. Wills-Karp Complement Activation Pathways: A Bridge between Innate and Adaptive Immune Responses in Asthma Proceedings of the ATS, July 1, 2007; 4(3): 247 - 251. [Abstract] [Full Text] [PDF]

				I. Kouznetsova, C. E. Chwieralski, R. Balder, M. Hinz, A. Braun, N. Krug, and W. Hoffmann Induced Trefoil Factor Family 1 Expression by Trans-Differentiating Clara Cells in a Murine Asthma Model Am. J. Respir. Cell Mol. Biol., March 1, 2007; 36(3): 286 - 295. [Abstract] [Full Text] [PDF]

				G. A. Melendi, S. J. Hoffman, R. A. Karron, P. M. Irusta, F. R. Laham, A. Humbles, B. Schofield, C.-H. Pan, R. Rabold, B. Thumar, et al. C5 Modulates Airway Hyperreactivity and Pulmonary Eosinophilia during Enhanced Respiratory Syncytial Virus Disease by Decreasing C3a Receptor Expression J. Virol., January 15, 2007; 81(2): 991 - 999. [Abstract] [Full Text] [PDF]

				S. M. Drouin, M. Sinha, G. Sfyroera, J. D. Lambris, and R. A. Wetsel A Protective Role for the Fifth Complement Component (C5) in Allergic Airway Disease Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 852 - 857. [Abstract] [Full Text] [PDF]

				C. B. Martin and B. K. Martin Characterization of the Murine C3a Receptor Enhancer-Promoter: Expression Control by an Activator Protein 1 Sequence and an Ets-Like Site J. Immunol., September 1, 2005; 175(5): 3123 - 3132. [Abstract] [Full Text] [PDF]

				A. G. Therien, R. Baelder, and J. Kohl Agonist Activity of the Small Molecule C3aR Ligand SB 290157 J. Immunol., June 15, 2005; 174(12): 7479 - 7480. [Full Text] [PDF]